Immune-related adverse events during adjuvant therapy with pembrolizumab for stage III melanoma are associated with longer recurrence-free survival, according to a secondary analysis of trial data.

Among more than 1000 patients treated in the EORTC 1325/KEYNOTE-054 trial with the anti-PD-1 agent pembrolizumab (Keytruda), those who had an immune-related adverse event were significantly more likely to survive longer without recurrence, compared with patients not having events.